Relay Therapeutics (RLAY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Relay Therapeutics (RLAY) is Neutral.

The composite score behind that read is -0.01, weighing +0.19 of bullish evidence against -0.21 bearish.

Relay Therapeutics last closed at $17.88, +2.70% on the session.

Against the IVW growth benchmark the position is +1.90% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

Relay Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Relay Therapeutics in the 20th percentile on return on equity, where 100 is best.

Relay Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $3.82B.

StockMap tracks Relay Therapeutics as the 56th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Relay Therapeutics ranks 118th of 381 in the group, against a group median of -0.08.